Teachers Advisors LLC grew its stake in shares of Intrexon (NYSE:XON) by 9.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 68,326 shares of the biotechnology company’s stock after purchasing an additional 5,623 shares during the period. Teachers Advisors LLC owned approximately 0.05% of Intrexon worth $787,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Third Security LLC raised its holdings in shares of Intrexon by 2.5% during the fourth quarter. Third Security LLC now owns 57,928,289 shares of the biotechnology company’s stock valued at $667,334,000 after purchasing an additional 1,423,236 shares during the period. Greenwich Wealth Management LLC acquired a new position in shares of Intrexon during the fourth quarter valued at about $576,000. Peregrine Capital Management LLC raised its holdings in shares of Intrexon by 10.7% during the fourth quarter. Peregrine Capital Management LLC now owns 645,596 shares of the biotechnology company’s stock valued at $7,437,000 after purchasing an additional 62,268 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Intrexon by 7,504.8% during the third quarter. JPMorgan Chase & Co. now owns 59,622 shares of the biotechnology company’s stock valued at $1,122,000 after purchasing an additional 58,838 shares during the period. Finally, Frontier Capital Management Co. LLC raised its holdings in shares of Intrexon by 139.0% during the fourth quarter. Frontier Capital Management Co. LLC now owns 276,284 shares of the biotechnology company’s stock valued at $3,183,000 after purchasing an additional 160,701 shares during the period. Hedge funds and other institutional investors own 75.95% of the company’s stock.
NYSE:XON opened at $17.94 on Friday. The company has a quick ratio of 1.67, a current ratio of 1.92 and a debt-to-equity ratio of 0.01. The stock has a market cap of $2,435.48, a PE ratio of -19.50 and a beta of 1.11. Intrexon has a one year low of $10.26 and a one year high of $26.99.
Intrexon (NYSE:XON) last posted its earnings results on Thursday, March 1st. The biotechnology company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.08. The company had revenue of $77.03 million during the quarter, compared to the consensus estimate of $48.16 million. Intrexon had a negative net margin of 50.61% and a negative return on equity of 16.94%. The firm’s revenue for the quarter was up 67.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.37) earnings per share. equities analysts predict that Intrexon will post -0.92 earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on XON shares. JPMorgan Chase reiterated a “neutral” rating and set a $18.00 price objective (down previously from $22.00) on shares of Intrexon in a report on Monday, March 5th. ValuEngine downgraded shares of Intrexon from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Zacks Investment Research raised shares of Intrexon from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. Bank of America decreased their target price on shares of Intrexon from $21.00 to $19.00 and set a “neutral” rating for the company in a research report on Friday, March 2nd. Finally, Northland Securities reissued a “buy” rating and set a $17.00 target price on shares of Intrexon in a research report on Friday, March 2nd. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. Intrexon has an average rating of “Hold” and an average price target of $34.67.
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon (NYSE:XON).
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.